Drug Type Small molecule drug |
Synonyms GD-0039 |
Target |
Action inhibitors |
Mechanism MAN2A1 inhibitors(Alpha-mannosidase 2A1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC8H16ClNO3 |
InChIKeyLIRVFCZWYJVKCV-XNJRRJNCSA-N |
CAS Registry214462-68-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chemotherapy-induced damage | Phase 2 | United States | - | - |
Colorectal Cancer | Phase 2 | Canada | - | |
Colorectal Cancer | Phase 2 | - | - | |
Cutaneous T-Cell Lymphoma | Phase 2 | France | - | - |
Cutaneous T-Cell Lymphoma | Phase 2 | - | - | |
Head and Neck Neoplasms | Phase 2 | Poland | - | - |
Head and Neck Neoplasms | Phase 2 | Russia | - | - |
Head and Neck Neoplasms | Phase 2 | - | - | |
Kidney Neoplasms | Phase 2 | United States | - | - |
Kidney Neoplasms | Phase 2 | Canada | - |